Researchers evaluate the effects of glucagon-like peptide-1 receptor agonists on kidney and cardiovascular outcomes.

The results showed that compared to placebo, GLP-1 receptor agonists reduced the risk of kidney failure by 16% and the worsening of kidney function by 22% (defined by a drop in estimated glomerular ...

GLP-1 RAs to assist with weight loss have exploded in popularity. Researchers are working to identify which patients will ...

GLP-1 receptor agonists were originally developed for the treatment of type 2 diabetes, and later of obesity, but there is growing evidence that their benefits extend far beyond reductions in blood ...

In recent years, GLP-1 agonist medications like Ozempic have ... which enhances digestive function and supports appetite regulation. TriBiome™ (Patented metabolic support) This innovative ...

Amneal Resubmits DHE Autoinjector New Drug Application and Receives U.S. FDA Approval of Exenatide, its First Generic Injectable GLP-1 Agonist ...

The potential health benefits of GLP-1 diabetes and weight loss meds keep piling up: New research shows they may also shield ...

Second, Amneal has received approval from the FDA for exenatide, which is the Company’s first generic injectable glucagon-like peptide-1 (GLP-1 ... changes in kidney function, low blood sugar ...

The potential health benefits of GLP-1 diabetes and weight loss meds keep piling up: New research shows they may also ...

GLP-1 drugs have shown potential not just for treating obesity and diabetes, pointed out Aaron Anselmo, CSO at VitaKey, but other conditions like cardiovascular disease and kidney disease as well. “As ...